Teriparatide for low bone turnover in advanced kidney disease
Treatments studied
Part of Bones, joints & muscles, Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests teriparatide (a hormone-like bone medicine) to improve bone health in people with advanced chronic kidney disease who are at risk for weak, low-turnover bone. It may help by changing how quickly your bones break down and rebuild.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have advanced chronic kidney disease (stage 4–5, or on dialysis) with eGFR 29 or lower.
- Your bone density scan (DXA) shows low bone strength, or you’ve had a past fragility fracture.
- Your doctors expect “adynamic/low-turnover bone disorder,” based on blood tests (low bone-building marker) and/or a bone biopsy.
- Your calcium blood level is not consistently too high (high calcium can exclude you).
- You can safely take teriparatide and provide informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether regulating parathyroid hormone (PTH) can improve bone density in people with advanced chronic kidney disease (CKD) who are not on dialysis. It may help you if you have stage 4-5 CKD and high PTH levels.
This trial looks at a personalized approach to diagnosing and treating bone problems caused by long-term kidney disease. It may help by matching treatment plans to the type of bone turnover found in your tests or biopsy.
This study checks how kidney disease affects bone health by measuring hormones like PTH and related blood markers. It may help doctors better diagnose bone problems that can occur with poor kidney function.
This study tests a daily injection that may help heal broken pelvic or leg bones faster in people with certain health conditions like diabetes or smoking. It is for adults 50 and older who have had a low-energy fracture.
This trial tests a daily injection called abaloparatide, which helps strengthen bones and reduce the chance of breaking a bone. It is for postmenopausal women with osteoporosis who are at higher risk of fractures.
This study tests whether giving teriparatide (a daily injection that helps build bone) at different times of day makes it work better for women with postmenopausal osteoporosis and very low bone density. If you qualify, you might get the medicine either in the morning or evening, and researchers will track how your bone density changes.
Hear when a new Cardiac Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.